CONTINUED STRONG SALES GROWTH AND SEK 73 MILLION PRIVATE PLACEMENT

SECOND QUARTER 2014 (APR – JUN)

• Net sales in the quarter amounted to SEK 18.5 (15.8) million, corresponding to
an increase of 17 percent in SEK. Sales increased by 15 percent in local
currency.

• Operating income before depreciation and amortization (EBITDA) amounted to SEK
1.8 (2.4) million, corresponding to an EBITDA margin of 10 percent.

• Net income amounted to SEK 0.8 (1.7) million, resulting in earnings per share
of SEK 0.04 (0.09).

• Cash flow from operating activities was SEK 0.8 (3.9) million.

• STEEN Solution™ and related products accounted for 23 (13) percent of total
sales.

• Investment in future sales growth is done through research and development of
new indications for STEEN Solution ™

• The board of directors resolved to issue new shares through a SEK 73 million
private placement directed to a group of qualified Swedish and international
investors in order to facilitate a faster build-up of the company’s working
capital for the US and European launch of XPS™ and STEEN Solution™ and also for
investment in new indications.

THE PERIOD 2014 (JAN – JUN)

• Net sales in the period amounted to SEK 36.7 (32.1) million, corresponding to
an increase of 14 percent in SEK. Sales increased by 12 percent in local
currency.

• Operating income before depreciation and amortization (EBITDA) amounted to SEK
4.9 (6.1) million, corresponding to an EBITDA margin of 13 percent.

• Net income amounted to SEK 2.6 (4.1) million, resulting in earnings per share
of SEK 0.13 (0.21).

• Cash flow from operating activities was SEK -2.6 (7.9) million due to changes
in trade payables that amounted to SEK -3.3 million and paid taxes that amounted
to SEK -3.6 million.

• STEEN Solution™ and related products accounted for 24 (14) percent of total
sales.

• The Advisory Panel convened by the FDA voted unanimously, by 10 votes to 0,
that the XPS™ System with STEEN Solution™ meets the requirements for HDE
(Humanitarian Device Exemption) approval.

• XPS™ (Xvivo Perfusion System) received a CE mark, allowing XPS™ and the
accompanying single-use products to be sold in Europe.

• The first lung transplant in Turkey using a lung treated with the STEEN
Solution™ method was performed at Sureyyapasa Teaching Hospital.

• The board of directors resolved to issue new shares through a SEK 73 million
private placement directed to a group of qualified Swedish and international
investors in order to facilitate a faster build-up of the company’s working
capital for the US and European launch of XPS™ and STEEN Solution™ and also for
investment in new indications.

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

• XVIVO has received market approval from the FDA for STEEN Solution™ and XPS™.

• XVIVO Perfusion’s share warrant program 2014/2016, offered to employees, was
fully subscribed.

• The private placement increased the number of shares and votes in XVIVO
Perfusion by 1,950,000 from 19,562,769 to 21,512,769.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on
Wednesday, August 13, 2014. Telephone: +44 (0) 1452 558567, enter code 67955875.
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on August 13, 2014 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com